Droplet-based microfluidic platform for intracellular ion channel drug discovery

Zagnoni, M. and Woolhead, C. (2018) Droplet-based microfluidic platform for intracellular ion channel drug discovery. Impact, 2018(7), pp. 68-70.

Zagnoni, M. and Woolhead, C. (2018) Droplet-based microfluidic platform for intracellular ion channel drug discovery. Impact, 2018(7), pp. 68-70.

[img]
Preview
Text
177936.pdf - Published Version
Available under License Creative Commons Attribution.

198kB

Abstract

New technology is widening the chance of developing new pharmacological compounds and has the potential to create new jobs and have economic and societal impact on healthcare. Economic impact: The average expenditure to develop and bring to market a new drug is estimated to be approximately $2 billion, with target identification, discovery and the development of a new chemical compound before clinical trials accounting for 30% of the total cost. Commercialization of the developed platform has potential to add considerable information over the gold standard obtained by current electrophysiological tests with automated patch-clamp technology and impact the pre-screening stages of compounds, most of which is currently provided as a service by CROs and/or CMOs. Therefore, outcomes from this project have potential to carve a unique sector in the market of drug screening instrumentation. To assess this impact and available opportunities, we have secured the participation of members from academia, healthcare technology and industry to act as an advisory board for consultancy regarding knowledge transfer and commercialisation. Industrial impact: The developed system will be tested in collaboration with project partner Apconix for the development of pharmacological assays based on combinatorial chemistry approaches. Outside the immediate benefit in identifying new active compounds for the CLIC4 channel, the potential for translating the developed procedures for other pharmacologically relevant eukaryotic ion channels present cost-saving arguments against current live-cell based, large-screening assay in the Pharmaceutical industry. In addition, the collaboration with project partner Smartox will explore a further application of the technology for use with limited resources of venom samples only available in extremely small quantities that currently elude industrial automated screening. The proposed technology has the potential to greatly impact drug discovery by identifying new efficient venom-derived drugs. Together, this double partnership will enable us to address different screening needs for both SME and the Pharmaceutical Industry. Societal impact: Identification of new drug candidates from the developed technology will expand the panel of drugs with implications in cancer, mitochondrial dysfunction and neurodegenerative diseases. Improving the efficacy of identified drugs at preclinical level is expected to improve outcomes during clinical trials. Therefore, wide societal benefits would be in the form of new medicine and their improved efficacy. Furthermore, the applicability of the proposed technology to the other identified applications (see academic beneficiaries) and healthcare related fields could impact the screening of vaccines and environmental toxins, all of which will produce massive societal benefits.

Item Type:Articles
Additional Information:Engineering and Physical Sciences Research Council Project ID: EP/ N031849/1.
Status:Published
Refereed:No
Glasgow Author(s) Enlighten ID:Woolhead, Dr Cheryl
Authors: Zagnoni, M., and Woolhead, C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Molecular Cell and Systems Biology
Journal Name:Impact
Publisher:Science Impact Ltd.
ISSN:2398-7073
ISSN (Online):2398-7081
Copyright Holders:Copyright © 2018 Science Impact Ltd.
First Published:First published in Impact 2018(7):68-70
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record